Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer

Nivolumab, a monoclonal antibody targeting programmed cell death-1, significantly prolongs survival for patients with advanced non-small-cell lung cancer (NSCLC). However, little is known about the value of predictive biomarkers. Hence, we investigated the impact of skeletal muscle (SM) mass loss on...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukagoshi, Mariko, Yokobori, Takehiko, Yajima, Toshiki, Maeno, Toshitaka, Shimizu, Kimihiro, Mogi, Akira, Araki, Kenichiro, Harimoto, Norifumi, Shirabe, Ken, Kaira, Kyoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035054/
https://www.ncbi.nlm.nih.gov/pubmed/32049805
http://dx.doi.org/10.1097/MD.0000000000019059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035054/
https://www.ncbi.nlm.nih.gov/pubmed/32049805
http://dx.doi.org/10.1097/MD.0000000000019059

Ejemplares similares